Trial Profile

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer a phase II randomised study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibudilast (Primary)
Indications Chemotherapy-induced damage
Focus Adverse reactions
Acronyms OXTOX

Most Recent Events

16 Apr 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2022.
16 Apr 2021 Status changed from not yet recruiting to recruiting.
11 Apr 2019 Anticipated date for last participant enrollment is 30 June 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com